Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Immunovant, Inc. (IMVT) had Normalized Pre-Tax Income of $-412.95M for the most recently reported fiscal year, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-413.84M |
|
-- |
|
-- |
|
-- |
|
$-438.15M |
|
-- |
|
$-412.95M |
|
|
Normalized Pre-Tax Income |
$-412.95M |
$-413.84M |
|
$-413.84M |
|
$-413.84M |
|
$-413.84M |
|
$-438.15M |
|
$-437.77M |
|
151.57M |
|
151.57M |
|
$-2.73 |
|
$-2.73 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$776.22M |
|
-- |
|
-- |
|
-- |
|
$68.78M |
|
$707.45M |
|
$707.45M |
|
$707.45M |
|
170.11M |
|
| Cash Flow Statement Financials | |
$-375.87M |
|
$-0.76M |
|
$454.49M |
|
$635.37M |
|
$713.97M |
|
$78.61M |
|
$49.49M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-376.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-58.50% |
|
-58.50% |
|
-53.31% |
|
-58.50% |
|
$4.16 |
|
$-2.48 |
|
$-2.48 |
|